COMPASS Pathways Plc Sponsored ADR CMPS 深 沪
等待开盘 05-14 09:30:00 美东时间
10.96
+1.590
+16.97%
华盛通- 最 高11.08
- 今 开9.85
- 成交量 862.52万股
- 最 低 9.61
- 昨 收 9.37
- 总市值 14.79亿
- 52周最高 11.08
- 市盈率 静 --
- 换手率 6.39%
- 52周最低 2.25
- 委 比 42.14%
- 总股本 1.35亿
- 历史最高 61.69
- 量 比 3.29
- 振 幅 15.69%
- 历史最低 2.25
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Transcript: Compass Pathways Q1 2026 Earnings Conference Call
Compass Pathways (NASDAQ:CMPS) reported first-quarter financial results on Wedn...
16分钟前
Compass Pathways Reports Strong Q1 Results, Shares Surge
COMPASS Pathways Plc (NASDAQ:CMPS) reported first-quarter earnings on Wednesday before the market open. Here's a rundown of the report.
05-13 23:05
Earnings Scheduled For May 13, 2026
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to re...
05-13 19:11
Compass Pathways Q1 EPS $(0.30) Beats $(0.34) Estimate
Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.34) by 11.76 percent. This is a 25 percent decrease over losses of $(0.24) per share from the
05-13 18:32
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive
Health officials explored restricting specific antidepressants among SSRI drugs-sourcesKennedy announced other steps to reduce use of the medicines on MondayKennedy says SSRIs are overprescribed and, without evidence,
05-09 00:02
美股大行评级 | 潜在涨幅85%！SoFi获机构升目标价至49美元；华尔街大行看涨AMD至400美元
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从28美元升至49美元；HC Wainwright & Co.：维持Fate Therapeutics"买入"评级，目标价从5美元升至7美元
05-05 11:40
GH Research prices $117.5M share offering
GH Research said on Wednesday it priced an underwritten U.S. offering of 6.53M ordinary shares at $18 each, for gross proceeds of about $117.5M The company is selling all of the shares in the offering...
04-29 20:41
美股大行评级 | 达美乐比萨惨遭10家大行下调目标价；铿腾电子、艾克尔科技、Relay 、辛普森配件制造、TFI International等获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Intellia Therapeutics"买入"评级，目标价从48美元升至58美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从7美元升至8美元
04-29 10:28
HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $70 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Compass Pathways (NASDAQ:CMPS) with a Buy and maintains $70 price target.
04-28 19:13
This AMD Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed outlook on Adobe, AMD, Campbell's, Lineage, and WR Berkley. See analyst ratings page. AMD stock: what analysts think.
04-27 21:12
